Jun. 11 at 11:31 AM
$XTNT just a few notes you may or may not know...
HEMOBLAST Bellows is typically the most cost-effective option on a per-unit and coverage basis.
Surgeon and financial sentiment regarding HEMOBLAST Bellows is strongly positive following a pivotal U.S. distribution agreement. The hemostatic agent is driving strong commercial growth and revenue upgrades in the medical sector, while surgeons praise its rapid application and efficacy. Clinical data indicates high preference among U.S. and European surgeons. Providers appreciate that it is the only combination powdered hemostat containing collagen, thrombin, and chondroitin sulfate, allowing it to control a broad range of bleeding without requiring reconstitution.
Xtant Medical acquired exclusive U.S. distribution rights for HEMOBLAST Bellows and brought on Dilon Technologies' dedicated sales team, vastly accelerating commercial reach into a multibillion-dollar hemostatic market.
Strategic mgmt of sales team is key to the bottom line.
